FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3616401> ?p ?o ?g. }

• W3616401 endingPage "8" @default.
• W3616401 startingPage "715" @default.
• W3616401 abstract "Malignant pleural mesothelioma (MPM) is an aggressive treatment-resistant tumor with a median survival from diagnosis of 12 months. Although multimodality protocols that combine aggressive surgery and adjuvant chemotherapy or radiotherapy have shown improved survival in selected cases, the majority of patients with MPM are not suitable for radical surgery due to advanced stage and comorbid medical illness. For these patients combination chemotherapy with Pemetrex and Cisplatin should be considered for first line palliative chemotherapy. The therapeutic options available to patients with MPM resistant or refractory to systemic chemotherapy are very limited. Thoracic stop-flow perfusion (TSP) is a semi-invasive loco-regional drug delivery system that, limiting the circulation to the thorax during the anticancer agent's infusion, claims the advantage of reaching high drug concentration at the tumor site while maintaining a low systemic toxicity. The aim of this phase I-II study was to evaluate the toxicity profile and efficacy of two different platinum-based combined regimens--cisplatin plus mitomycin-C (MMC) and cisplatin plus melphalan (L-PAM)--administered using TSP technique in patients with advanced or recurrent MPM who had refractory disease after systemic first line chemotherapy. Patients with histologically proven unresectable stage II-III MPM entered this trial. Between January 1995 and December 2001, 27 patients were enrolled in the study and submitted to TSP using the two different chemotherapy cisplatin based regimens: 12 patients received cisplatin 100 mg/m2 plus MMC 20 mg/m2 (MMC arm) and 15 cisplatin 100 mg/m2 plus L-PAM 50 mg/m2 (L-PAM arm). Objective responses were assessed by CT-scan 30 and 60 days after the end of treatment in all 27 enrolled patients. Two patients (7.4%) achieved a complete response, 2 (7.4%) a partial response and 4 (14.8%) a minor response. The remaining 19 patients (70.3%) showed a stable disease. No patients developed progression of the disease following the first TSP. The overall median time to progression was 8.9 months (range 1-41). The median survival time for all patients from the beginning of regional chemotherapy was 16.6 months, with a 1-year survival rate of 62.9%, a 2-year survival rate of 18.5%, and a 3-year survival rate of 7.4%. Our data show that TSP is a relatively effective second-line treatment in patients with progressive disease after systemic chemotherapy, with a low rate of major complications and treatment-related toxicity." @default.
• W3616401 created "2016-06-24" @default.
• W3616401 creator A5005403632 @default.
• W3616401 creator A5011224332 @default.
• W3616401 creator A5018226027 @default.
• W3616401 creator A5021954675 @default.
• W3616401 creator A5043872623 @default.
• W3616401 creator A5062348172 @default.
• W3616401 creator A5068476902 @default.
• W3616401 date "2007-01-06" @default.
• W3616401 modified "2023-09-23" @default.
• W3616401 title "Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial." @default.
• W3616401 cites W1995190573 @default.
• W3616401 cites W2021219775 @default.
• W3616401 cites W2028269517 @default.
• W3616401 cites W2049341077 @default.
• W3616401 cites W2055708804 @default.
• W3616401 cites W2057434277 @default.
• W3616401 cites W2102627969 @default.
• W3616401 cites W2114866480 @default.
• W3616401 cites W2139248078 @default.
• W3616401 cites W2144671372 @default.
• W3616401 cites W2153219264 @default.
• W3616401 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17203752" @default.
• W3616401 hasPublicationYear "2007" @default.
• W3616401 type Work @default.
• W3616401 sameAs 3616401 @default.
• W3616401 citedByCount "0" @default.
• W3616401 crossrefType "journal-article" @default.
• W3616401 hasAuthorship W3616401A5005403632 @default.
• W3616401 hasAuthorship W3616401A5011224332 @default.
• W3616401 hasAuthorship W3616401A5018226027 @default.
• W3616401 hasAuthorship W3616401A5021954675 @default.
• W3616401 hasAuthorship W3616401A5043872623 @default.
• W3616401 hasAuthorship W3616401A5062348172 @default.
• W3616401 hasAuthorship W3616401A5068476902 @default.
• W3616401 hasConcept C121332964 @default.
• W3616401 hasConcept C126322002 @default.
• W3616401 hasConcept C141071460 @default.
• W3616401 hasConcept C142424586 @default.
• W3616401 hasConcept C142724271 @default.
• W3616401 hasConcept C143998085 @default.
• W3616401 hasConcept C2776694085 @default.
• W3616401 hasConcept C2777407522 @default.
• W3616401 hasConcept C2778239845 @default.
• W3616401 hasConcept C2778822529 @default.
• W3616401 hasConcept C2780258809 @default.
• W3616401 hasConcept C71924100 @default.
• W3616401 hasConcept C87355193 @default.
• W3616401 hasConceptScore W3616401C121332964 @default.
• W3616401 hasConceptScore W3616401C126322002 @default.
• W3616401 hasConceptScore W3616401C141071460 @default.
• W3616401 hasConceptScore W3616401C142424586 @default.
• W3616401 hasConceptScore W3616401C142724271 @default.
• W3616401 hasConceptScore W3616401C143998085 @default.
• W3616401 hasConceptScore W3616401C2776694085 @default.
• W3616401 hasConceptScore W3616401C2777407522 @default.
• W3616401 hasConceptScore W3616401C2778239845 @default.
• W3616401 hasConceptScore W3616401C2778822529 @default.
• W3616401 hasConceptScore W3616401C2780258809 @default.
• W3616401 hasConceptScore W3616401C71924100 @default.
• W3616401 hasConceptScore W3616401C87355193 @default.
• W3616401 hasIssue "6A" @default.
• W3616401 hasLocation W36164011 @default.
• W3616401 hasOpenAccess W3616401 @default.
• W3616401 hasPrimaryLocation W36164011 @default.
• W3616401 hasRelatedWork W2018028995 @default.
• W3616401 hasRelatedWork W2026791198 @default.
• W3616401 hasRelatedWork W2100029565 @default.
• W3616401 hasRelatedWork W2149504117 @default.
• W3616401 hasRelatedWork W2176768908 @default.
• W3616401 hasRelatedWork W2361287035 @default.
• W3616401 hasRelatedWork W2373945807 @default.
• W3616401 hasRelatedWork W2381460883 @default.
• W3616401 hasRelatedWork W2746579122 @default.
• W3616401 hasRelatedWork W4250154484 @default.
• W3616401 hasVolume "20" @default.
• W3616401 isParatext "false" @default.
• W3616401 isRetracted "false" @default.
• W3616401 magId "3616401" @default.
• W3616401 workType "article" @default.